1. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs;Kortejärvi;Journal of pharmaceutical sciences,2010
2. Food and Drug Administration (FDA). Guidance for Industry: Waiver on In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2017 [cited 2020 Jun 20]. Available from: https://www.fda.gov/media/70963/download.
3. European Medicine Agency (EMA). Guideline on the investigation of bioequivalence. 2010 [cited 2020 Jun 20]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf.
4. World Health Organization (WHO). Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability (Annex 6). 2015 [cited 2020 Jun 20]. Available from: https://www.who.int/medicines/areas/quality_safety/quality_assurance/trs1003_annex6.pdf?ua=1.
5. Brazilian Health Surveillance Agency (ANVISA). The publication of the list of pharmaceuticals applied for bio-protection based on the biopharmaceutical class system (SCB). 2014 [cited 2020 Jun 20]. Available from: http://portal.anvisa.gov.br/documents/33836/349509/IN%2B07%2B2014.pdf/0996340b-24e54855-8bfd-0756765e422e?version=1.0.